Maximizing NIR-II Fluorescence: IR-1061 Liposome Design Advances

Study Background and Research Question

Fluorescence imaging (FI) in the near-infrared II (NIR-II, 1000–1700 nm) window is emerging as a powerful modality for deep tissue visualization due to reduced photon scattering and minimal biological autofluorescence. These characteristics enable higher spatial resolution and penetration depth compared to visible or NIR-I imaging, supporting a broad spectrum of in vivo applications such as angiography, tumor delineation, and hemodynamic monitoring (source: paper). Despite advances, the translation of organic near infrared fluorescent dyes into clinical and preclinical research has faced challenges—including dye instability, low quantum yield, and poor solubility in aqueous environments. The paper by Yu et al. directly addresses these hurdles, focusing on the cyanine-based dye IR-1061, which exhibits a strong NIR-II emission peak around 1064 nm and a relatively high quantum yield for organic fluorophores.

Key Innovation from the Reference Study

The central innovation reported by Yu et al. is the rational design and systematic optimization of IR-1061-loaded liposomal nanosystems for maximized fluorescence performance in vivo. The study uniquely dissects the interplay between liposome surface charge and dye aggregation state, revealing how these factors govern encapsulation efficiency and emission characteristics (source: paper). By manipulating phospholipid charge and controlling IR-1061 concentration within the liposome, the authors demonstrate how to avoid fluorescence-quenching aggregation and achieve persistent, high-contrast vascular imaging.

Methods and Experimental Design Insights

The authors synthesized a range of liposomal formulations using phospholipids of varying charge (cationic, neutral, anionic) and systematically loaded them with different concentrations of IR-1061. The encapsulation effect was quantified by fluorescence intensity measurements and encapsulation efficiency assays. The conformational state of IR-1061 (free versus aggregated) within the liposomes was probed through spectral analysis. In vivo imaging was performed in mouse models to evaluate the spatial resolution, circulation time, and angiographic capabilities of the optimized formulation (IR1061-ALP-N3). Key methodological insights include:

• Liposome charge is a critical variable: anionic liposomes yielded the highest encapsulation efficiency and fluorescence, while cationic types performed worst due to less favorable electrostatic interactions with the hydrophobic, weakly anionic IR-1061 (source: paper).
• IR-1061 displays concentration-dependent photophysical behavior—remaining in a monomeric (free) state at lower concentrations, but aggregating at higher loadings, which severely quenches fluorescence.
• The aggregation threshold is determined by the limited internal space of the liposome and the local dye concentration.
• In vivo studies included time-course imaging of vascular structures to assess both immediate and long-term performance.

Core Findings and Why They Matter

Yu et al. reported several critical findings:

• Anionic liposomes provide superior encapsulation and preserve IR-1061's fluorescence, attributed to favorable electrostatic and hydrophobic interactions (source: paper).
• High IR-1061 concentrations within liposomes induce dye aggregation, reducing emission intensity—meaning there is an optimal dye loading that maximizes brightness.
• The optimized IR-1061-liposome (IR1061-ALP-N3) achieved high-resolution, clear systemic angiography in mice and maintained strong vascular fluorescence for over 16 hours post-injection, enabling long-term vascular imaging (source: paper).
• Compared to inorganic NIR-II probes (e.g., quantum dots, rare-earth nanoparticles), the organic IR-1061 system offers improved biocompatibility and faster excretion, making it more attractive for translational research.

These results provide a practical blueprint for designing high-performance, organic NIR-II fluorescent dye systems with real-world applicability in molecular and deep tissue imaging workflows.

Protocol Parameters

• formulation type | anionic liposome | in vivo NIR-II angiography | maximizes encapsulation and fluorescence of IR-1061 | paper
• IR-1061 loading concentration | < threshold for aggregation (empirically determined) | fluorescence imaging | ensures dye remains in free, emissive state | paper
• excitation wavelength | ~980 nm | NIR-II fluorescence imaging | matches IR-1061 absorbance for optimal excitation | paper
• emission detection window | 1064 nm (peak) | vascular imaging | aligns with IR-1061 emission maximum | paper
• storage of IR-1061 solution | use freshly prepared, avoid long-term storage | all experimental setups | maintains dye stability and fluorescence | product_spec
• solvent for IR-1061 stock | DMSO (≥25.65 mg/mL) | stock preparation | ensures full solubilization; not soluble in ethanol/water | product_spec

Comparison with Existing Internal Articles

The findings of Yu et al. align well with recent workflow recommendations and mechanistic insights from the broader literature on IR-1061:

• "Optimizing IR-1061 Near Infrared Fluorescent Dye for In Vivo Imaging" (see internal resource) offers practical tips for encapsulation and troubleshooting, echoing the reference study's emphasis on the critical role of formulation in optimizing fluorescence output.
• "H-Aggregated IR-1061 Enables Synergistic NIR-II Imaging and PTT" (see internal resource) explores the functional consequences of IR-1061 aggregation in lipids, demonstrating how controlled aggregation states can be harnessed for dual imaging and therapy—complementary to the aggregation avoidance approach highlighted by Yu et al.
• "Polystyrene Nanoparticles Enhance IR-1061 NIR Imaging for Deep Tissue" (internal resource) examines alternative carrier systems, further validating that matrix composition and surface chemistry are decisive for probe performance in vivo.

These articles collectively reinforce that the choice of matrix and control of dye state are universal determinants for successful application of near infrared fluorescent dyes in biomedical research.

Limitations and Transferability

While the rational design principles presented by Yu et al. are robust, several limitations remain:

• The study is focused on murine models; translation to larger animals or human subjects will require additional safety and pharmacokinetic validation.
• Encapsulation and imaging performance may vary with different tissue types or disease models, necessitating protocol adjustments for specific research needs (workflow_recommendation).
• The optimal IR-1061 loading must be empirically determined for each liposome batch, since aggregation thresholds are sensitive to subtle formulation changes.
• While the work contrasts organic and inorganic NIR-II probes, it does not address long-term fate or clearance in non-vascular tissues.

Research Support Resources

For researchers aiming to implement or extend these approaches, IR-1061 (SKU C8242) is available as a high-quality near infrared fluorescent dye specifically suited for in vivo NIR-II imaging applications. The compound is supplied as a solid and should be handled as a fresh DMSO solution, given its insolubility in water and ethanol and sensitivity to long-term storage (product_spec). For further details on best practices and troubleshooting with IR-1061, see the referenced internal protocols and mechanistic articles. APExBIO provides IR-1061 with comprehensive quality control, making it a reliable resource for advanced imaging workflows.